Go Pro
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel Free EUDA Stock Alerts

EUDA Health (EUDA) Competitors

EUDA Health logo
$13.64 +2.35 (+20.75%)
As of 02:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

EUDA vs. BNR, XGN, PARK, SERA, and PIII

Should you buy EUDA Health stock or one of its competitors? MarketBeat compares EUDA Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with EUDA Health include Burning Rock Biotech (BNR), Exagen (XGN), Park Dental Partners (PARK), Sera Prognostics (SERA), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry.

How does EUDA Health compare to Burning Rock Biotech?

EUDA Health (NASDAQ:EUDA) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

EUDA Health has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. EUDA Health's return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
EUDA HealthN/A N/A N/A
Burning Rock Biotech -11.57%-10.98%-7.33%

In the previous week, EUDA Health had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 1 mentions for EUDA Health and 0 mentions for Burning Rock Biotech. EUDA Health's average media sentiment score of 0.00 equaled Burning Rock Biotech'saverage media sentiment score.

Company Overall Sentiment
EUDA Health Neutral
Burning Rock Biotech Neutral

EUDA Health has higher earnings, but lower revenue than Burning Rock Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EUDA Health$6.82M5.98-$2.77MN/AN/A
Burning Rock Biotech$77.16M1.34-$7.92M-$0.82N/A

4.4% of EUDA Health shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

EUDA Health has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

EUDA Health currently has a consensus target price of $55.00, indicating a potential upside of 303.08%. Given EUDA Health's stronger consensus rating and higher probable upside, research analysts plainly believe EUDA Health is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EUDA Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

EUDA Health beats Burning Rock Biotech on 9 of the 13 factors compared between the two stocks.

How does EUDA Health compare to Exagen?

Exagen (NASDAQ:XGN) and EUDA Health (NASDAQ:EUDA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, EUDA Health had 1 more articles in the media than Exagen. MarketBeat recorded 1 mentions for EUDA Health and 0 mentions for Exagen. Exagen's average media sentiment score of 0.00 equaled EUDA Health'saverage media sentiment score.

Company Overall Sentiment
Exagen Neutral
EUDA Health Neutral

EUDA Health has a net margin of 0.00% compared to Exagen's net margin of -29.49%. EUDA Health's return on equity of 0.00% beat Exagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Exagen-29.49% -94.37% -28.96%
EUDA Health N/A N/A N/A

Exagen currently has a consensus target price of $9.11, indicating a potential upside of 94.89%. EUDA Health has a consensus target price of $55.00, indicating a potential upside of 303.08%. Given EUDA Health's higher probable upside, analysts clearly believe EUDA Health is more favorable than Exagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exagen
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90
EUDA Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

EUDA Health has lower revenue, but higher earnings than Exagen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exagen$66.57M1.70-$19.95M-$0.89N/A
EUDA Health$6.82M5.98-$2.77MN/AN/A

Exagen has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, EUDA Health has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

75.3% of Exagen shares are owned by institutional investors. Comparatively, 4.4% of EUDA Health shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Exagen and EUDA Health tied by winning 7 of the 14 factors compared between the two stocks.

How does EUDA Health compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and EUDA Health (NASDAQ:EUDA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Park Dental Partners presently has a consensus target price of $21.75, suggesting a potential upside of 13.71%. EUDA Health has a consensus target price of $55.00, suggesting a potential upside of 303.08%. Given EUDA Health's higher probable upside, analysts clearly believe EUDA Health is more favorable than Park Dental Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Park Dental Partners
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
2 Strong Buy rating(s)
2.75
EUDA Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Park Dental Partners has higher revenue and earnings than EUDA Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Park Dental Partners$244.49M0.35-$360K$0.7425.85
EUDA Health$6.82M5.98-$2.77MN/AN/A

In the previous week, EUDA Health had 1 more articles in the media than Park Dental Partners. MarketBeat recorded 1 mentions for EUDA Health and 0 mentions for Park Dental Partners. Park Dental Partners' average media sentiment score of 0.00 equaled EUDA Health'saverage media sentiment score.

Company Overall Sentiment
Park Dental Partners Neutral
EUDA Health Neutral

Company Net Margins Return on Equity Return on Assets
Park Dental PartnersN/A N/A N/A
EUDA Health N/A N/A N/A

4.4% of EUDA Health shares are held by institutional investors. 10.6% of Park Dental Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Park Dental Partners and EUDA Health tied by winning 5 of the 10 factors compared between the two stocks.

How does EUDA Health compare to Sera Prognostics?

Sera Prognostics (NASDAQ:SERA) and EUDA Health (NASDAQ:EUDA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Sera Prognostics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, EUDA Health has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

EUDA Health has a net margin of 0.00% compared to Sera Prognostics' net margin of -56,385.97%. EUDA Health's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sera Prognostics-56,385.97% -41.02% -30.95%
EUDA Health N/A N/A N/A

EUDA Health has higher revenue and earnings than Sera Prognostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sera Prognostics$80K1,000.54-$31.93M-$0.65N/A
EUDA Health$6.82M5.98-$2.77MN/AN/A

In the previous week, EUDA Health had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 1 mentions for EUDA Health and 0 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.00 equaled EUDA Health'saverage media sentiment score.

Company Overall Sentiment
Sera Prognostics Neutral
EUDA Health Neutral

Sera Prognostics currently has a consensus price target of $5.50, indicating a potential upside of 169.08%. EUDA Health has a consensus price target of $55.00, indicating a potential upside of 303.08%. Given EUDA Health's higher possible upside, analysts clearly believe EUDA Health is more favorable than Sera Prognostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sera Prognostics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
EUDA Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 4.4% of EUDA Health shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

EUDA Health beats Sera Prognostics on 7 of the 13 factors compared between the two stocks.

How does EUDA Health compare to P3 Health Partners?

EUDA Health (NASDAQ:EUDA) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, EUDA Health and EUDA Health both had 1 articles in the media. EUDA Health's average media sentiment score of 0.00 equaled P3 Health Partners'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
EUDA Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
P3 Health Partners
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

4.4% of EUDA Health shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

EUDA Health has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

EUDA Health currently has a consensus target price of $55.00, suggesting a potential upside of 303.08%. P3 Health Partners has a consensus target price of $14.00, suggesting a potential upside of 34.87%. Given EUDA Health's higher probable upside, equities research analysts clearly believe EUDA Health is more favorable than P3 Health Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EUDA Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

EUDA Health has a net margin of 0.00% compared to P3 Health Partners' net margin of -8.57%.

Company Net Margins Return on Equity Return on Assets
EUDA HealthN/A N/A N/A
P3 Health Partners -8.57%N/A -19.99%

EUDA Health has higher earnings, but lower revenue than P3 Health Partners.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EUDA Health$6.82M5.98-$2.77MN/AN/A
P3 Health Partners$1.46B0.05-$147.95M-$38.60N/A

Summary

EUDA Health beats P3 Health Partners on 5 of the 9 factors compared between the two stocks.

Get EUDA Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for EUDA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EUDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EUDA vs. The Competition

Export
MetricEUDA HealthMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$40.80M$1.81B$6.81B$12.34B
Dividend YieldN/AN/A2.67%9.36%
P/E RatioN/A76.1427.1624.06
Price / Sales5.9826.44573.91113.10
Price / CashN/A27.2929.0548.09
Price / Book-6.045.4210.686.17
Net Income-$2.77M-$54.76M$3.59B$331.63M
7 Day Performance28.63%-1.82%-1.50%-1.48%
1 Month Performance-14.40%0.58%1.17%-1.20%
1 Year Performance-78.34%-3.90%24.50%17.62%

EUDA Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EUDA
EUDA Health
1.8095 of 5 stars		$13.65
+20.8%		$55.00
+303.1%		-81.1%$40.80M$6.82MN/A2
BNR
Burning Rock Biotech
0.7392 of 5 stars		$9.30
-6.4%		N/A+112.1%$104.55M$514.43MN/A1,390
XGN
Exagen
2.6387 of 5 stars		$4.30
+5.1%		$9.11
+111.9%		-37.3%$98.81M$68.38MN/A220
PARK
Park Dental Partners
2.1815 of 5 stars		$19.61
-2.1%		$21.75
+10.9%		N/A$90.48M$244.49M26.501,212
SERA
Sera Prognostics
2.9761 of 5 stars		$2.16
+9.1%		$5.50
+154.6%		-29.8%$77.53M$80KN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EUDA) was last updated on 7/20/2026 by MarketBeat.com Staff.
From Our Partners
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel
They Crashed the Dollar 40% Before. It's Happening Again.
In 1985, world powers deliberately drove the dollar lower in a coordinated deal that drained everyday savers. ...
Priority Gold | Sponsoredtc pixel
They proved it worked in '76. Then buried it.
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
#1 Power Grid Stock Right Now
The U.S. power grid is cracking - and one company's technology is already generating round-the-clock power in ...
Altimetry | Sponsoredtc pixel